New Anticoagulants in Atrial Fibrillation

ABSTRACT

Atrial fibrillation (AF) requires anticoagulation for prevention of arterial embolism, especially in the presence of defined risk factors summarized in the CHADS₂ score (congestive heart disease, hypertension, age >75 years, diabetes, history of ischemic stroke or transient cerebral ischemia). Vitamin K antagonists as drugs of choice have several limitations. International normalized ratio (INR) adjustment to 2.0 to 3.0 may be difficult to maintain, and doses vary widely between patients. Inherited variations of the vitamin K epoxide reductase C1 enzyme and of the cytochrome P450 2C9 system influence the dosage as well as exogenous factors such as food and drug intake or intercurrent diseases. Increasing age and risk of falling are the main factors behind the underuse of anticoagulation in AF. Anticoagulants with a lack of all or most of these characteristics and without need of regular monitoring for dose adjustment may improve the adherence to the indication for anticoagulation. Indirect systemic and oral direct factor Xa and oral direct thrombin inhibitors are currently being developed for the prevention of embolism in patients with AF.

KEYWORDS

Atrial fibrillation - oral anticoagulants - idraparinux - oral factor Xa inhibitor - oral thrombin inhibitor

REFERENCES

• 1 Hart R G, Pearce L A, Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;  146(12) 857-867
• 2 Go A S, Hylek E M, Henault L E et al.. Prevalence of diagnosed atrial fibrillation: national implications for management and stroke prevention: the ATRIA study.  Circulation. 1999;  100(suppl) 1-397
• 3 Hylek E M, Go A S, Chang Y et al.. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.  N Engl J Med. 2003;  349(11) 1019-1026
• 4 Albers G W, Diener H C, Frison L SPORTIF Executive Steering Committee for the SPORTIF V Investigators et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.  JAMA. 2005;  293(6) 690-698
• 5 Connolly S, Pogue J, Hart R ACTIVE Writing Group of the ACTIVE Investigators et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.  Lancet. 2006;  367(9526) 1903-1912
• 6 Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice.  Int J Clin Pract. 2006;  60(3) 258-264
• 7 Hirsh J, O'Donnell M, Eikelboom J W. Beyond unfractionated heparin and warfarin: current and future advances.  Circulation. 2007;  116(5) 552-560
• 8 Singer D E, Albers G W, Dalen J E American College of Chest Physicians et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, suppl) 546S-592S
• 9 Johnson C E, Lim W K, Workman B S. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.  J Am Geriatr Soc. 2005;  53(4) 655-659
• 10 van der Meer F J, Rosendaal F R, Vandenbroucke J P, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.  Arch Intern Med. 1993;  153(13) 1557-1562
• 11 Hutten B A, Lensing A W, Kraaijenhagen R A, Prins M H. Safety of treatment with oral anticoagulants in the elderly. A systematic review.  Drugs Aging. 1999;  14(4) 303-312
• 12 Pengo V, Legnani C, Noventa F, Palareti G. ISCOAT Study Group. (Italian Study on Complications of Oral Anticoagulant Therapy) . Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study.  Thromb Haemost. 2001;  85(3) 418-422
• 13 Atrial Fibrillation Investigators . Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.  Arch Intern Med. 1994;  154(13) 1449-1457
• 14 The Stroke Prevention in Atrial Fibrillation Investigators . Bleeding during antithrombotic therapy in patients with atrial fibrillation.  Arch Intern Med. 1996;  156(4) 409-416
• 15 Fang M C, Chang Y, Hylek E M et al.. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.  Ann Intern Med. 2004;  141(10) 745-752
• 16 Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients.  Arch Intern Med. 2004;  164(18) 2044-2050
• 17 Schulman S, Beyth R J, Kearon C, Levine M N. American College of Chest Physicians . Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, suppl) 257S-298S
• 18 Bates S M, Weitz J I. The status of new anticoagulants.  Br J Haematol. 2006;  134(1) 3-19
• 19 Eikelboom J W, Weitz J I. A replacement for warfarin: the search continues.  Circulation. 2007;  116(2) 131-133
• 20 Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic.  Curr Top Med Chem. 2005;  5(16) 1677-1695
• 21 Bauer K A. New anticoagulants.  Curr Opin Hematol. 2008;  15(5) 509-515
• 22 Turpie A GG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.  Arterioscler Thromb Vasc Biol. 2007;  27(6) 1238-1247
• 23 Ma Q, Fareed J. Idraparinux sodium. Sanofi-Aventis.  IDrugs. 2004;  7(11) 1028-1034
• 24 Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss C. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.  Eur J Clin Pharmacol. 2008;  64(6) 555-563
• 25 Herbert J M, Hérault J P, Bernat A et al.. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.  Blood. 1998;  91(11) 4197-4205
• 26 Bijsterveld N R, Vink R, van Aken B E et al.. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers.  Br J Haematol. 2004;  124(5) 653-658
• 27 PERSIST investigators . A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation.  J Thromb Haemost. 2004;  2(1) 47-53
• 28 Buller H R, Cohen A T, Davidson B van Gogh Investigators et al. Idraparinux versus standard therapy for venous thromboembolic disease.  N Engl J Med. 2007;  357(11) 1094-1104
• 29 Buller H R, Cohen A T, Davidson B van Gogh Investigators et al. Extended prophylaxis of venous thromboembolism with idraparinux.  N Engl J Med. 2007;  357(11) 1105-1112
• 30 Harenberg J, Vukojevic Y, Mikus G, Joerg I, Weiss C. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials.  J Thromb Haemost. 2008;  6(5) 890-892
• 31 Savi P, Herault J P, Duchaussoy P et al.. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.  J Thromb Haemost. 2008;  6(10) 1697-1706
• 32 Bousser M G, Bouthier J, Büller H R Amadeus Investigators et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.  Lancet. 2008;  371(9609) 315-321
• 33 Buller H R, Destors J M, Gallus A S. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin.  , [abstract 32] Blood. 2008;  112 18
• 34 Ansell J. Factor Xa or thrombin: is factor Xa a better target?.  J Thromb Haemost. 2007;  5(Suppl 1) 60-64
• 35 Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.  Expert Opin Investig Drugs. 2006;  15(8) 843-855
• 36 Agnelli G, Gallus A, Goldhaber S Z ODIXa-DVT Study Investigators et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.  Circulation. 2007;  116(2) 180-187
• 37 Buller H R, Lensing A W, Prins M H Einstein-DVT Dose-Ranging Study investigators et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.  Blood. 2008;  112(6) 2242-2247
• 38 Pinto D J, Orwat M J, Koch S et al.. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.  J Med Chem. 2007;  50(22) 5339-5356
• 39 Raghavan N, Frost C E, Yu Z et al.. Apixaban metabolism and pharmacokinetics after oral administration to humans.  Drug Metab Dispos. 2009;  37(1) 74-81
• 40 Wong P C, Crain E J, Xin B et al.. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.  J Thromb Haemost. 2008;  6(5) 820-829
• 41 Frost C, Yu Z, Moore K. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects.  J Thromb Haemost. 2007;  5(suppl 2) P-M-664
• 42 Buller H, Deitchman D, Prins M, Segers A. Botticelli Investigators, Writing Committee . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.  J Thromb Haemost. 2008;  6(8) 1313-1318
• 43 Iwatsuki Y, Shigenaga T, Moritani Y et al.. Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor [ASH Annual Meeting Abstracts, Abstract 911].  Blood. 2006;  108
• 44 Eriksson B I, Quinlan D J, Weitz J I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development.  Clin Pharmacokinet. 2009;  48(1) 1-22
• 45 Eriksson B I, Turpie A GG, Lassen M R ONYX study group et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.  J Thromb Haemost. 2007;  5(8) 1660-1665
• 46 Zafar M U, Vorchheimer D A, Gaztanaga J et al.. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.  Thromb Haemost. 2007;  98(4) 883-888
• 47 Weitz J I, Connolly S TJ, Kunitada S. Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation [abstract 33].  Blood. 2008; 
• 48 Linkins L A, Weitz J I. Pharmacology and clinical potential of direct thrombin inhibitors.  Curr Pharm Des. 2005;  11(30) 3877-3884
• 49 Weitz J I. Factor Xa or thrombin: is thrombin a better target?.  J Thromb Haemost. 2007;  5(5, suppl 1) 65-67
• 50 Weitz J I, Büller H R. Direct thrombin inhibitors in acute coronary syndromes: present and future.  Circulation. 2002;  105(8) 1004-1011
• 51 Gustafsson D, Nyström J, Carlsson S et al.. The direct thrombin inhibitor Melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.  Thromb Res. 2001;  101(3) 171-181
• 52 Wolzt M, Sarich T S, Eriksson U G. Pharmacokinetics and pharmacodynamics of ximelagatran.  Semin Vasc Med. 2005;  5(3) 245-253
• 53 Diener H C. Executive Steering Committee of the SPORTIFF III and V Investigators . Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.  Cerebrovasc Dis. 2006;  21(4) 279-293
• 54 Boudes P F. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee.  Contemp Clin Trials. 2006;  27(5) 432-440
• 55 Lee W M, Larrey D, Olsson R et al.. Hepatic findings in long-term clinical trials of ximelagatran.  Drug Saf. 2005;  28(4) 351-370
• 56 Gurewich V. Ximelagatran—promises and concerns.  JAMA. 2005;  293(6) 736-739
• 57 Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.  Br J Clin Pharmacol. 2007;  64(3) 292-303
• 58 Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.  Clin Pharmacokinet. 2008;  47(1) 47-59
• 59 Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.  Br J Clin Pharmacol. 2007;  64(3) 292-303
• 60 Ezekowitz M D, Reilly P A, Nehmiz G et al.. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).  Am J Cardiol. 2007;  100(9) 1419-1426
• 61 Connolly S J, Ezekowitz M D, Salim Yusuf S et al.. Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2009;  , in press